Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01815359
Other study ID # 12-289
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date March 2013
Est. completion date September 2026

Study information

Verified date February 2024
Source Memorial Sloan Kettering Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is the first randomized trial comparing Early post-operative intraperitoneal chemotherapy (EPIC) and hyperthermic intraperitoneal chemotherapy (HIPEC) for appendiceal and colorectal cancer. The purpose of this study is to find out what effects, good and/or bad, EPIC and HIPEC after cytoreductive surgery have on the patient and the appendiceal, rectal or colon cancer.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 292
Est. completion date September 2026
Est. primary completion date September 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patient's age 18 years or older, both genders. - Clinical diagnosis of appendiceal or colorectal neoplasm with peritoneal mucinosis or metastasis. - Patient must be planning to undergo complete cytoreduction of all peritoneal disease. - ECOG performance status = 1. - Hematology: ANC = 1,500/ µL; Platelets > 75,000/ µL. - Adequate Renal function Creatinine <1.5 x the upper limit of normal (ULN) or calculated creatinine clearance of = 50ml/min. - Adequate Hepatic function: Bilirubin less than 1.5mg/dL; (except in patients with Gilbert's Syndrome, who must have a total bilirubin less than 3.0mg/dL). - Women with childbearing potential who are negative for pregnancy test (urine or blood) and who agree to use effective contraceptive method. Reliable contraception should be used from trial screening and must be continued throughout the study. A woman of childbearing potential is defined as one who is biologically capable of becoming pregnant. - A man participating in this study must agree to utilize reliable barrier form of contraception for the duration of the study. - Signed and dated written informed consent to participate in this clinical trial must be obtained prior to any study procedure. - Subjects with a history of endometrial cancer are eligible only if they presented with a stage lower than 1A and if the histology was a subtype other than poorly differentiated. Exclusion Criteria: - Subjects who have previously undergone intraperitoneal chemotherapy. - Subjects with classical carcinoid - Tumors of low malignant potential - Other prior malignancies, except for cured non-melanoma skin cancer, curatively treated in situ carcinoma of the cervix, adequately treated malignancies for which there has been no evidence of activity for more than 3 years or indolent tumors for which observation over three years is a reasonable option. - Presence of clinically apparent or suspected metastasis to sites other than lymph nodes or peritoneal surfaces. - Women who are pregnant or lactating. - Subjects with a condition which may interfere with the subjects' ability to understand the requirements of the study. - Active coronary artery disease (defined as unstable angina or a positive cardiac stress test). - Subjects with a history of coronary artery disease may be included if they have had a normal stress test within 60 days of enrollment and/or were cleared by MSK cardiology. - Uncontrolled hypertension defined as >140/90 and not cleared for surgery at the time of consent. - New York Heart Association (NYHA) Class II or higher Congestive heart failure. - Restrictive or obstructive pulmonary disease that would limit study compliance or place the patient at unacceptable risk for participation in the study. - History of cerebrovascular disease. that would limit study compliance or place the patient at unacceptable risk for participation in the study. - Subjects with other concurrent severe medical problems unrelated to the malignancy that would significantly limit full compliance with the study or places them at an unacceptable risk for participation in the study. - Patients with known floxuridine, leucovorin ,or mitomycin allergy. - Evidence of extensive intraperitoneal adhesions at the time of surgery which prohibits intraperitoneal therapy, as determined by the operating surgeon. - Any condition that would preclude the ability to deliver appropriate IP therapy. - Use of an oral medication, lacking a suitable non-oral substitute, that if held for up to ten days, would be felt an unacceptable risk by the investigator. - Life expectancy < 12 weeks.

Study Design


Intervention

Procedure:
Cytoreductive Surgery
Optimal Surgical Debulking
Drug:
HIPEC with Mitomycin-C

EPIC with FUDR and Leucovorin


Locations

Country Name City State
United States Memorial Sloan Kettering Basking Ridge (Consent and Follow up) Basking Ridge New Jersey
United States Memorial Sloan Kettering Commack (Consent and Follow up) Commack New York
United States Memorial Sloan Kettering Westchester (Consent and Follow up) Harrison New York
United States University of Miami Miami Florida
United States Memorial Sloan Kettering Monmouth (Consent and Follow up) Middletown New Jersey
United States Memorial Sloan Kettering Bergen (Consent and Follow up) Montvale New Jersey
United States Memorial Sloan Kettering Cancer Center New York New York
United States Washington University School of Medicine Saint Louis Missouri
United States Memorial Sloan Kettering Nassau (Consent and Follow up) Uniondale New York

Sponsors (6)

Lead Sponsor Collaborator
Memorial Sloan Kettering Cancer Center Brigham and Women's Hospital, The Cleveland Clinic, University of Miami, University of Pittsburgh Medical Center, Washington University School of Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary disease-free survival Documentation of tumor recurrence will be made based on surveillance CT/PET CT scans at time points as determined by attending radiologist, with clinical correlation from the treating physician. 3 years
Secondary surgical toxicity grade 3 to 5 We will evaluate toxicity up to 30 days postoperatively for any surgical Grade 3-5 complications/toxicites or chemotherapy related Grade 4 or 5 toxicities. Surgical morbidity will be graded using the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 up to 60 days
Secondary chemotherapy toxicity grade 3 to 5 We will evaluate toxicity up to 30 days postoperatively for any surgical Grade 3-5 complications/toxicities or chemotherapy related Grade 4 or 5 toxicities. up to 60 days
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT00098787 - Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05425940 - Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer Phase 3
Suspended NCT04595604 - Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery. N/A
Completed NCT03414125 - Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening N/A
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT03874026 - Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03167125 - Participatory Research to Advance Colon Cancer Prevention N/A
Completed NCT03181334 - The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation N/A
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Recruiting NCT05568420 - A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Completed NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Phase 1
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A